Precision BioSciences (DTIL) came out with a quarterly loss of $2.13 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to earnings of $3.46 per share a year ago. These ...

Precision BioSciences Inc., a clinical-stage company developing gene editing therapies for diseases with high unmet need, has ...

Precision is advancing the final U.S. investigational new drug (IND)-enabling toxicology studies with an anticipated IND and/or clinical trial application (CTA) filing targeted by the end of 2025 with ...

Precision BioSciences has a solid financial position with a significant cash reserve, extending its operational runway well into the latter half of 2026. Upcoming clinical milestones, particularly ...